definiens: ) to theORIGINAL LICENSE as defined below, is made by and between the BOARD OF REGENTS ( ) of THE UNIVERSITYOF TEXAS SYSTEM ( ), an agency of the State of Texas, whose address is 201 West Street, Austin, Texas 78701,on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER ( hereinafter ), a componentinstitution of SYSTEM, and ARONEX PHARMACEUTICALS, INC ., a Delaware corporation having a principal place ofbusiness located at 3 Forbes Road, Lexington, Massachusetts 02421 ( ), a wholly - owned subsidiary ofANTIGENICS INC ., a Delaware corporation . BOARD and LICENSEE may be referred to hereafter collectively as theRECITALSA . BOARD and LICENSEE ( as successor in interest to ARGUS PHARMACEUTICALS, INC . ) are parties to that certainExclusive License Agreement dated effective as of July 22, 1988 ( such Exclusive License Agreement, as amended as describedin more detail below, referred to herein as the ) ; B. BOARD and LICENSEE desire to further amend the ORIGINAL LICENSE